Clinical Trial Update: Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating salmeterol inhalation powder (salmeterol xinafoate) delivered via HandiHaler 2 and Serevent Diskus in patients with chronic ob…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SEREVENT DISKUS (SALMETEROL XINAFOATE)
• Salmeterol inhalation powder (salmeterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED